PDCD1 and head and neck squamous cell carcinoma: Currently, immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, blocking the PD-1/PD-L1 axis, have been approved for the treatment of patients with HNSCC who have disease progression or failed platinum-based chemotherapy [2–5].